Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Free Cash Flow (2016 - 2026)

Tenax Therapeutics' Free Cash Flow history spans 8 years, with the latest figure at -$1.3 million for Q4 2017.

  • On a quarterly basis, Free Cash Flow rose 58.71% to -$1.3 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$12.1 million, a 23.49% increase, with the full-year FY2025 number at -$35.8 million, down 141.89% from a year prior.
  • Free Cash Flow hit -$1.3 million in Q4 2017 for Tenax Therapeutics, down from -$1.2 million in the prior quarter.
  • Over the last five years, Free Cash Flow for TENX hit a ceiling of -$741223.0 in Q1 2013 and a floor of -$9.0 million in Q4 2015.
  • Historically, Free Cash Flow has averaged -$3.2 million across 5 years, with a median of -$3.0 million in 2014.
  • Biggest five-year swings in Free Cash Flow: tumbled 266.3% in 2014 and later surged 71.33% in 2017.
  • Tracing TENX's Free Cash Flow over 5 years: stood at -$2.0 million in 2013, then increased by 1.53% to -$2.0 million in 2014, then crashed by 352.35% to -$9.0 million in 2015, then soared by 65.37% to -$3.1 million in 2016, then skyrocketed by 58.71% to -$1.3 million in 2017.
  • Business Quant data shows Free Cash Flow for TENX at -$1.3 million in Q4 2017, -$1.2 million in Q3 2017, and -$5.6 million in Q2 2017.